Results 201 to 210 of about 34,385 (232)

Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature [PDF]

, 2011
Buadi, F, Dingli, D, Dispenzieri, A., Gertz, M, Greipp, P, Hayman, S, Kumar, S, Kyle, R, Lacy, M, Lust, J, Morice, W, Rajkumar, S, Russell, S, SIRAGUSA, Sergio, Witzig, T, Zeldenrust, S   +15 more
core  

Primary cerebral low-grade B-cell lymphoma, monoclonal immunoglobulin deposition disease, cerebral light chain deposition disease and “aggregoma”: an update on classification and diagnosis [PDF]

core   +1 more source

Amyloid cardiomyopathy presenting with gastrointestinal symptoms of abdominal pain, back pain, and constipation: A case report. [PDF]

Medicine (Baltimore)
Zhang Y, Zhang T, Zhao M, Li P, Xie J, Xie J.   +5 more
europepmc   +1 more source

Serum and Tissue Light-Chains as Disease Biomarkers in AL Amyloidosis. [PDF]

Int J Mol Sci
Aimo A, Ferrari Chen YF, Chianca M, Mori F, Pucci A, Castiglione V, Musetti V, Caponi L, Fabiani I, Vergaro G, Franzini M, Emdin M, Cardinale D.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment

American journal of hematology/oncology, 2023
Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain are deposited in tissues.
M. Gertz
semanticscholar   +1 more source

Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis

Acta Haematologica, 2020
Immunoglobulin light-chain amyloidosis (AL) is a disease with limited treatment options due to the frailty of patients caused by organ damage. Since the clonal plasma cells often contain the cytogenetic aberration t(11;14), the Bcl-2 inhibitor venetoclax
Charlotte Gran, Johanna Borg Bruchfeld, F. Ellin, H. Nahi   +3 more
semanticscholar   +1 more source

Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside

Expert Review of Hematology, 2020
Introduction Immunoglobulin light chain (AL) amyloidosis is one of the most frequent systemic amyloidosis in Western countries. It is caused by a B-cell clone producing a misfolded light chain (LC) that deposits in organs.
M. Basset, M. Nuvolone, G. Palladini, G. Merlini   +3 more
semanticscholar   +1 more source

Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis

Amyloid: Journal of Protein Folding Disorders, 2020
Background: The aim of the present prospective study (ClinicalTrials.gov Identifier: NCT02111538) was to assess the prognostic value of phase angle (PhA), derived from bioimpedance vectorial analysis (BIVA), in patients affected by systemic amyloid light-
R. Caccialanza, E. Cereda, C. Klersy, P. Milani, S. Cappello, V. Martinelli, A. Turri, M. Basset, V. Borioli, M. Nuvolone, M. Caraccia, F. Lavatelli, S. Masi, F. Lobascio, A. Foli, G. Merlini, G. Palladini   +16 more
semanticscholar   +1 more source

Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency

Amyloid: Journal of Protein Folding Disorders, 2019
Systemic immunoglobulin light-chain (AL) amyloidosis is a plasma cell disorder characterized by immunoglobulin light chain deposition in various organs and tissues [1].
Xia Wu, Hui-lei Miao, T. Zhu, Jun Feng, Lu Zhang, Y. Mao, Dao-bin Zhou, Xin-xin Cao, Jian Li, Xia Wu   +9 more
semanticscholar   +1 more source